WHAT: Researchers at the National Institutes of Health (NIH) have identified a new genetic syndrome characterized by a constellation of health problems, including severe allergy, immune deficiency, autoimmunity and motor and neurocognitive impairment. The researchers, led by scientists at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), observed that the syndrome’s diverse symptoms are the result of mutations in a single gene associated with sugar metabolism. They plan to evaluate certain types of sugars as a potential treatment for people with this rare genetic condition in an upcoming clinical trial.
The study, published in the Journal of Allergy and Clinical Immunology, involved eight patients from two families. The families were originally referred to NIH because of severe eczema and recurrent skin and lung infections. By studying this group, the investigators found that the syndrome is caused by mutations in the PGM3 gene that result in the production of underactive PGM3 protein. The NIH team showed that underactive PGM3 leads to lower levels of sugars that are essential for glycosylation, or the attachment of sugars to proteins. Glycosylation is necessary for the normal growth and function of all tissues and organs in the human body. The variety of symptoms in people with PGM3 mutations likely reflects the production of abnormally glycosylated proteins throughout the body. In the laboratory, adding a certain type of sugar to cells from patients with PGM3 mutations boosted cellular levels of the sugars necessary for glycosylation, thus suggesting a potential treatment.
The NIH scientists have yet to unravel how glycosylation defects influence the immune systems of people with PGM3 mutations. However, their findings suggest that other, less severe defects in glycosylation may play a role in more common allergic and immunologic diseases, opening potential new avenues for developing treatments. The study was conducted by scientists from NIAID, the National Human Genome Research Institute and the National Institute of Neurological Disorders and Stroke, all components of NIH, and collaborators. Additional funding was provided by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases, under grant number R01DK55615, and by The Rocket Fund.
Y Zhang et al. Autosomal recessive PGM3 mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. Journal of Allergy and Clinical Immunology DOI: 10.1016/j.jaci.2014.02.013 (2014).
Joshua Milner, M.D., Chief of the Allergic Inflammation Unit in NIAID’s Laboratory of Allergic Diseases, and Helen Su, M.D., Ph.D., Chief of the Human Immunological Diseases Unit in NIAID’s Laboratory of Host Defenses, are available to comment on the findings.
To schedule interviews, please contact Hillary Hoffman, (301) 402-1663, [email protected]
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health ®